Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01193
|
|||||
| Drug Name |
Prasterone
|
|||||
| Synonyms |
17-Chetovis; 17-Hormoforin; 3beta-hydroxyandrost-5-en-17-one; 5,6-Dehydroisoandrosterone; 5,6-Dehydroisoandrostorone; 5,6-Didehydroisoandrosterone; 5-Dehydroepiandrosterone; 53-43-0; Andrestenol; Androstenolone; Caswell No 051F; DHEA; Dehydro-epi-androsterone; Dehydroepiandrosterone; Dehydroisoandrosterone; Diandron; Diandrone; Epiandrosterone, 5-dehydro-; Intrarosa; PRASTERONE; Prasterona; Prasteronum; Prestara; Psicosterone; Siscelar plus; trans-Dehydroandrosterone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hypercalcemia [ICD11: 5B91.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H28O2
|
|||||
| Canonical SMILES |
CC12CCC3C(C1CCC2=O)CC=C4C3(CCC(C4)O)C
|
|||||
| InChI |
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1
|
|||||
| InChIKey |
FMGSKLZLMKYGDP-USOAJAOKSA-N
|
|||||
| CAS Number |
CAS 53-43-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 288.4 | Topological Polar Surface Area | 37.3 | ||
| Heavy Atom Count | 21 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103302695
, 104095449
, 11446567
, 12014907
, 12146065
, 14751238
, 14775640
, 17404931
, 1983
, 24278369
, 24702275
, 26703947
, 29224908
, 3135651
, 4449
, 46387028
, 46508824
, 47193749
, 47959958
, 48413520
, 48415849
, 49681751
, 49747225
, 49857278
, 50172721
, 53777474
, 53788218
, 56312069
, 56312916
, 56313484
, 56313819
, 56320669
, 56320670
, 57323014
, 596018
, 75250
, 7885884
, 8145544
, 8153636
, 837865
, 841442
, 87566797
, 91692812
, 92297484
, 92303742
, 92308678
, 92309040
, 92709895
, 93167098
, 96025095
|
|||||
| ChEBI ID |
ChEBI:28689
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
| MRP8 | Transporter Info | Multidrug resistance-associated protein 8 | Substrate | [4] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [5] | ||
| References | ||||||
| 1 | Prasterone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 3 | Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. | |||||
| 4 | Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57. | |||||
| 5 | Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.